

---

**CBE ID**

3389

**Title**

Concurrent Use of Opioids and Benzodiazepines (COB)

**Endorsement Status**

Endorsed

**Is Under Review**

No

**Next Maintenance Cycle**

Spring 2027

**Previous Endorsement Cycle**

Spring 2021

**Initial Endorsement**

Fri, 10/26/2018 - 04:52

**Steward**

Pharmacy Quality Alliance

**1.0 New or Maintenance**

Maintenance

**1.1 Measure Structure**

Single Measure

**1.3 Electronic Clinical Quality Measure (eCQM)**

No

**1.6 Measure Description**

The percentage of individuals  $\geq 18$  years of age with concurrent use of prescription opioids and benzodiazepines during the measurement year.

A lower rate indicates better performance.

**1.7 Measure Type**

Process

**1.8 Level of Analysis**

Health Plan

**1.13 Data Dictionary**

Not attached. I attest that all information will be provided where codes and/or value sets are needed (1.14a - 1.15c).

### **1.14 Numerator**

The number of individuals from the denominator with concurrent use of opioids and benzodiazepines for  $\geq 30$  cumulative days during the measurement year.

### **1.15 Denominator**

The denominator includes individuals  $\geq 18$  years of age with  $\geq 2$  prescription claims for opioid medications on different dates of service and with  $\geq 15$  cumulative days' supply during the measurement year. Individuals with cancer, sickle cell disease, or in hospice are excluded.

### **1.20 Types of Data Sources**

Claims Data

### **6.1.2 Current or Planned Use(s)**

Public Reporting

### **6.1.3 Current Use(s)**

Public Reporting

### **Exclusions**

Individuals with cancer, sickle cell disease, or in hospice at any point during the measurement year are excluded from the denominator.

### **Measure Disclaimer**

This measure is not intended for clinical-decision-making. This measure is intended for retrospective evaluation of populations of patients and should not be used to guide clinical decisions for individual patients. For clinical guidance on opioid prescribing, see the Center for Disease Control and Prevention CDC Guideline for Prescribing Opioids for Chronic Pain [[https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm?CDC\\_AA\\_refVal=https...](https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm?CDC_AA_refVal=https...)] and Guideline Resources [<https://www.cdc.gov/drugoverdose/prescribing/resources.html>].

### **Risk Adjustment**

No risk adjustment or risk stratification

### **The measure developer is different from the measure steward**

Yes

### **Steward Organization**

Pharmacy Quality Alliance

### **Steward Organization URL**

<https://www.pqaalliance.org/>

---

## Steward POC email

bshirley@pqaalliance.org